Penni Black, PhD

1. A microRNA gene expression signature predicts response to erlotinib in epithelial cancer cell lines and targets EMT. Bryant JL, Britson J, Balko JM, Willian M, Timmons R, Frolov A and Black EP. Br J Cancer 106:148-56, 2012.
2. A gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer. Balko JM and Black EP. BMC Cancer 9:145, 2009.
3. MEK and EGFR inhibition demonstrate synergistic activity in EGFR-dependent NSCLC. Balko JM, Jones BR, Coakley VL and Black EP. Cancer Biol Ther 8:522-30, 2009.
4. Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors. Balko JM, Potti A, Saunders C, Stromberg A, Haura EB and Black EP. BMC Genomics 7:289, 2006.

Cancer Center Member

Research Focus

Programs

• Drug Discovery, Delivery and Translational Therapeutics

College & Department

• College of Pharmacy
• Department of Pharmaceutical Sciences

Insurance Information

Insurance policies can vary widely. Please check with your doctor/clinic for specific insurance information before your visit or procedure to avoid unexpected out-of-pocket costs. See list of insurers